EXEL EXELIXIS, INC.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 939767 · Fiscal year ends 01/01
Financial factors as of 2026-10-02 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY9.1%
TTM net income YoY30.6%
TTM EPS YoY40.3%
Revenue 3-yr CAGR12.1%
Net income 3-yr CAGR112.6%
Margins
Gross margin96.3%
Operating margin40.2%
Net margin35.5%
FCF margin46.5%
EBITDA margin41.3%
Returns
ROE44.3%
ROA33.2%
ROIC (approx.)47.8%
Asset turnover0.94x
Leverage & solvency
Liabilities / assets27.0%
Debt / equity0.00x
Current ratio3.21x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.33x
Accruals ratio-10.8%
Payout ratio—
Capex / revenue0.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252026-01-02 | FY20242025-01-03 |
|---|---|---|
| Income statement | ||
| Revenue | $2.32B | $2.17B |
| Cost of revenue | $83.70M | $76.22M |
| Gross profit | $2.24B | $2.09B |
| R&D expense | $825.00M | $910.41M |
| SG&A expense | $518.73M | $492.13M |
| Operating income | $872.19M | $604.62M |
| Income tax | $158.64M | $160.37M |
| Net income | $782.57M | $521.27M |
| EBITDA | $901.25M | $633.42M |
| EPS (basic) | 2.88 | 1.80 |
| EPS (diluted) | 2.78 | 1.76 |
| Weighted avg. shares (diluted) | 281.86M | 296.13M |
| Balance sheet | ||
| Cash & equivalents | $482.49M | $217.37M |
| Short-term investments | $576.60M | $893.90M |
| Receivables | $286.92M | $265.44M |
| Inventory | $21.69M | $22.39M |
| Current assets | $1.44B | $1.47B |
| PP&E, net | $98.96M | $119.39M |
| Goodwill | $63.68M | $63.68M |
| Total assets | $2.84B | $2.95B |
| Current liabilities | $405.64M | $403.77M |
| Total liabilities | $683.10M | $703.49M |
| Shareholders' equity | $2.16B | $2.24B |
| Shares outstanding | 262.48M | 281.73M |
| Cash flow statement | ||
| Operating cash flow | $884.27M | $699.97M |
| Capital expenditure | $8.43M | $28.43M |
| Free cash flow | $875.84M | $671.54M |
| Investing cash flow | $350.44M | -$116.78M |
| Financing cash flow | -$969.59M | -$628.81M |
| Depreciation & amortization | $29.05M | $28.80M |
| Stock-based compensation | $112.98M | $93.84M |
| Share buybacks | $947.51M | $652.03M |
Free plan shows the latest 2 periods; Pro shows all 19 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.